1. Oral Prostanoids and PAH

3. Goals and Learning Objectives

4. Program Overview

5. Oral Compounds That Target the Prostacyclin Pathway

6. Pathophysiologic Pathways Targeted by PAH Therapies

7. FDA Approved PAH Therapies

8. Risk Stratification of Patients ESC/ERS Guidelines

9. High-Risk Patients Not Candidates for Oral Prostanoids

10. Treatment Goal To Achieve Low-Risk Status

11. Treatment Algorithm ESC/ERS Guidelines

12. Intermediate-Risk Patients Potential Candidates for Oral Prostanoids

13. Example of a Potential Candidate for Oral Prostanoid

15. FREEDOM-C and FREEDOM-C2 Results

16. Complexities of Using Oral Treprostinil Role of Support Staff

17. Selexipag

20. Summary

21. Abbreviations

22. Abbreviations (cont)

23. Abbreviations (cont)

24. References

25. References (cont)

26. References (cont)